Acadia Pharmaceuticals (ACAD) Cash from Operations Growth (3y) (2013 - 2026)
Acadia Pharmaceuticals (ACAD) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - | - |
| 10 | Acadia Pharmaceuticals | 4.31 Bn | 3.46 Bn | 243.27 Mn | 57.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.34% |
| Dec 31, 2025 | -26.89% |
| Sep 30, 2025 | 370.54% |
| Jun 30, 2025 | 90.13% |
| Mar 31, 2025 | 31.35% |
| Dec 31, 2024 | 55.31% |
| Sep 30, 2024 | 78.70% |
| Jun 30, 2024 | 44.03% |
| Mar 31, 2024 | 35.42% |
| Dec 31, 2023 | 72.20% |
| Sep 30, 2023 | -37.27% |
| Jun 30, 2023 | 30.50% |
| Mar 31, 2023 | 28.47% |
| Dec 31, 2022 | 7.05% |
| Sep 30, 2022 | 66.21% |
| Jun 30, 2022 | 30.08% |
| Mar 31, 2022 | -5.95% |
| Dec 31, 2021 | 16.05% |
| Sep 30, 2021 | 26.10% |
| Jun 30, 2021 | 14.75% |